Myxofibrosarcoma
diseaseOn this page
Also known as fibromyxosarcomaMFSmyxoid fibrous histiocytomamyxoid malignant fibrous histiocytomamyxoid MFH
Summary
Myxofibrosarcoma (MONDO:0019202) is a disease and 20 clinical trials. Top therapeutic interventions include pazopanib, dexrazoxane, and ifosfamide. A subtype of soft tissue sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Clinical trials: 20
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | myxofibrosarcoma |
| Mondo ID | MONDO:0019202 |
| Orphanet | 79105 |
| DOID | DOID:0080534 |
| ICD-11 | 405689402 |
| NCIT | C6496 |
| SNOMED CT | 253042009 |
| UMLS | C3714524 |
| MedGen | 811359 |
| GARD | 0018941 |
| MedDRA | 10066948 |
| Is cancer (heuristic) | no |
Also known as: fibromyxosarcoma · MFS · myxofibrosarcoma · myxoid fibrous histiocytoma · myxoid malignant fibrous histiocytoma · myxoid MFH
Data availability: 22 cell lines.
Disease family
This is a subtype of soft tissue sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › soft tissue sarcoma › myxofibrosarcoma
Related subtypes (45): esophagus sarcoma, bladder sarcoma, penile sarcoma, trachea sarcoma, retroperitoneal sarcoma, paranasal sinus sarcoma, pancreas sarcoma, vagina sarcoma, undifferentiated pleomorphic sarcoma, central nervous system sarcoma, ovarian sarcoma, liver sarcoma, lung sarcoma, laryngeal sarcoma, breast sarcoma, extraosseous osteosarcoma, rhabdoid tumor, mediastinum sarcoma, prostate sarcoma, gallbladder sarcoma, testis sarcoma, anus sarcoma, clear cell sarcoma, kidney sarcoma, thyroid sarcoma, heart sarcoma, small intestinal sarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma, vulva sarcoma, intimal sarcoma, skin sarcoma, myxosarcoma, synovial sarcoma, alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, angiosarcoma, epithelioid sarcoma, extraskeletal Ewing sarcoma, SMARCA4-deficient sarcoma of thorax, desmoplastic small round cell tumor, undifferentiated round cell sarcoma, stromal sarcoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 20.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02180867 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery |
| NCT06370871 | PHASE3 | WITHDRAWN | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma |
| NCT04332874 | PHASE2 | RECRUITING | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg |
| NCT04480502 | PHASE2 | ACTIVE_NOT_RECRUITING | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma |
| NCT06239272 | PHASE1/PHASE2 | RECRUITING | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) |
| NCT07169344 | PHASE2 | RECRUITING | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma |
| NCT07173972 | PHASE2 | RECRUITING | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. |
| NCT01653028 | PHASE2 | COMPLETED | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma |
| NCT02584309 | PHASE2 | COMPLETED | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma |
| NCT02601209 | PHASE1/PHASE2 | TERMINATED | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma |
| NCT03425279 | PHASE1/PHASE2 | COMPLETED | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma |
| NCT03651375 | PHASE2 | UNKNOWN | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall |
| NCT04906876 | PHASE2 | WITHDRAWN | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas |
| NCT05116800 | PHASE2 | WITHDRAWN | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma |
| NCT04420975 | PHASE1 | ACTIVE_NOT_RECRUITING | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma |
| NCT05711615 | PHASE1 | RECRUITING | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma |
| NCT06789172 | PHASE1 | RECRUITING | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors |
| NCT03009201 | PHASE1 | COMPLETED | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery |
| NCT04242238 | PHASE1 | COMPLETED | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas |
| NCT06526897 | Not specified | NOT_YET_RECRUITING | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PAZOPANIB | 4 | 4 |
| DEXRAZOXANE | 4 | 3 |
| IFOSFAMIDE | 4 | 2 |
| DACTINOMYCIN | 4 | 1 |
| SELINEXOR | 4 | 1 |
| ALISERTIB | 3 | 1 |
| BRIGIMADLIN | 3 | 1 |
| ENVAFOLIMAB | 3 | 1 |
| EZABENLIMAB | 3 | 1 |
| VIMSELTINIB | 3 | 1 |
| ELRAGLUSIB | 2 | 2 |
| SAPANISERTIB | 2 | 1 |
| EFROFILCON A | 1 | 1 |
| NEDISERTIB | 1 | 1 |
| CHEMBL4068768 | 0 | 1 |
| CHEMBL4171277 | 0 | 1 |
| CHEMBL3962632 | 0 | 1 |
| CHEMBL3991933 | 0 | 1 |
| CHEMBL4748391 | 0 | 1 |